Patents by Inventor Leonard Larry Winneroski, Jr.
Leonard Larry Winneroski, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140256933Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 22, 2014Publication date: September 11, 2014Applicant: Eli Lilly and CompanyInventors: James Peter BECK, Steven James GREEN, Jose Eduardo LOPEZ, Brian Michael MATHES, Dustin James MERGOTT, Warren Jaye PORTER, Zoran RANKOVIC, Yuan SHI, Brian Morgan WATSON, Leonard Larry WINNEROSKI, JR.
-
Patent number: 8772282Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 4, 2013Date of Patent: July 8, 2014Assignee: Eli Lilly and CompanyInventors: James Peter Beck, Steven James Green, Jose Eduardo Lopez, Brian Michael Mathes, Dustin James Mergott, Warren Jaye Porter, Zoran Rankovic, Yuan Shi, Brian Morgan Watson, Leonard Larry Winneroski, Jr.
-
Publication number: 20140094454Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 4, 2013Publication date: April 3, 2014Applicant: Eli Lilly and CompanyInventors: James Peter BECK, Steven James GREEN, Jose Eduardo LOPEZ, Brian Michael MATHES, Dustin James MERGOTT, Warren Jaye PORTER, Zoran RANKOVIC, Yuan SHI, Brian Morgan WATSON, Leonard Larry WINNEROSKI, JR.
-
Publication number: 20130261111Abstract: The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Applicant: Eli Lilly and CompanyInventors: James Peter BECK, Steven James GREEN, Jose Eduardo LOPEZ, Brian Michael MATHES, Dustin James MERGOTT, Warren Jaye PORTER, Zoran RANKOVIC, Yuan SHI, Brian Morgan WATSON, Leonard Larry WINNEROSKI, JR
-
Patent number: 8088776Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.Type: GrantFiled: April 19, 2007Date of Patent: January 3, 2012Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
-
Patent number: 7994176Abstract: The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity.Type: GrantFiled: April 24, 2007Date of Patent: August 9, 2011Assignee: Eli Lilly and CompanyInventors: Renhua Li, Thomas Edward Mabry, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu
-
Patent number: 7968585Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.Type: GrantFiled: April 25, 2007Date of Patent: June 28, 2011Assignee: Eli Lilly and CompanyInventors: Thomas Edward Mabry, Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Leonard Larry Winneroski, Jr.
-
Publication number: 20110009395Abstract: The present invention provides BACE inhibitors of Formula I: methods for their use, intermediates, and methods for their preparation.Type: ApplicationFiled: July 6, 2010Publication date: January 13, 2011Applicant: ELI LILLY AND COMPANYInventors: James Edmund AUDIA, Dustin James MERGOTT, Grant Mathews VAUGHT, Brian Morgan WATSON, Leonard Larry WINNEROSKI, JR., Chongsheng Eric SHI
-
Publication number: 20100184764Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.Type: ApplicationFiled: March 19, 2010Publication date: July 22, 2010Applicant: ELI LILLY AND COMPANYInventors: Thomas Daniel AICHER, Mark Joseph CHICARELLI, Ronald Jay HINKLIN, Hongqi TIAN, Owen Brendan WALLACE, John Gordon ALLEN, Zhaogen CHEN, Thomas Edward MABRY, Jefferson Ray MCCOWAN, Nancy June SNYDER, Leonard Larry WINNEROSKI, JR.
-
Patent number: 7713979Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.Type: GrantFiled: October 26, 2005Date of Patent: May 11, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, John Gordon Allen, Zhaogen Chen, Thomas Edward Mabry, Jefferson Ray McCowan, Nancy June Snyder, Leonard Larry Winneroski, Jr.
-
Patent number: 7655641Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.Type: GrantFiled: February 10, 2004Date of Patent: February 2, 2010Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
-
Patent number: 7608639Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.Type: GrantFiled: October 8, 2004Date of Patent: October 27, 2009Assignee: Eli Lilly and CompanyInventors: Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
-
Publication number: 20090156571Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.Type: ApplicationFiled: April 19, 2007Publication date: June 18, 2009Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
-
Publication number: 20090111800Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.Type: ApplicationFiled: April 5, 2007Publication date: April 30, 2009Inventors: Thomas Daniel Aicher, Peter Biagio Anzeveno, Renhua Li, Alexei Pavlovych Krasutsky, Thomas Edward Mabry, Ashraf Saeed, Nancy June Snyder, Gregory Alan Stephenson, Hongqi Tian, Owen Brendan Wallace, Leonard Larry Winneroski, JR., Yanping Xu
-
Publication number: 20090099182Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.Type: ApplicationFiled: April 24, 2007Publication date: April 16, 2009Inventors: Renhua Li, Thomas Edward Mabry, Owen Brendan Wallace, Leonard Larry Winneroski, JR., Yanping Xu
-
Publication number: 20090099180Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.Type: ApplicationFiled: April 25, 2007Publication date: April 16, 2009Inventors: Thomas Edward Mabry, Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Leonard Larry Winneroski, JR.
-
Patent number: 7351728Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.Type: GrantFiled: July 14, 2005Date of Patent: April 1, 2008Assignee: Eli Lilly and CompanyInventors: Dawn Alisa Brooks, Scott Eugene Conner, Samuel James Dominianni, Alexander Glenn Godfrey, Lynn Stacy Gossett, Christopher John Rito, Allie Edward Tripp, Alan M. Warshawsky, Leonard Larry Winneroski, Jr., Guoxin Zhu
-
Patent number: 6982278Abstract: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubsituted or substituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is H, alkyl or haloalkyl. R4 is H, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.Type: GrantFiled: August 23, 2001Date of Patent: January 3, 2006Assignee: Eli Lilly and CompanyInventors: Dawn Alisa Brooks, Scott Eugene Conner, Samuel James Dominianni, Alexander Glenn Godfrey, Lynn Stacy Gossett, Christopher John Rit, Allie Edward Tripp, Alan M. Warshawsky, Leonard Larry Winneroski, Jr., Guoxin Zhu
-
Patent number: 6541497Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.Type: GrantFiled: March 3, 2000Date of Patent: April 1, 2003Assignee: Eli Lilly and CompanyInventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
-
Patent number: 6353027Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.Type: GrantFiled: March 3, 2000Date of Patent: March 5, 2002Assignee: Eli Lilly and CompanyInventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.